<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754465</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-SHEET-102</org_study_id>
    <nct_id>NCT03754465</nct_id>
  </id_info>
  <brief_title>Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers</brief_title>
  <official_title>A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of
      ALLO-ASC-SHEET in subjects with Diabetic Foot Ulcers, compared to placebo therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Active Group: ALLO-ASC-SHEET

        2. Control Group: Hydrogel SHEET (vehicle control)

        3. Study Type: Interventional

        4. Study Design: Randomized, Comparator-controlled, Double-blind, multi-center study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to initial complete wound closure between the two groups</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in wound size compared to baseline between the two groups</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups</measure>
    <time_frame>During 12 weeks(at every visit during treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of complete wound closure</measure>
    <time_frame>Follow up to 24 weeks from the initial complete wound closure.</time_frame>
    <description>Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrogel SHEET(Vehicle control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-DFU</intervention_name>
    <description>Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer</description>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <other_name>Hydrogel sheet containing Allogenic Mesenchymal Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hydrogel SHEET(Vehicle control)</intervention_name>
    <description>Application of Hydrogel SHEET to diabetic foot ulcer</description>
    <arm_group_label>Hydrogel SHEET(Vehicle control)</arm_group_label>
    <other_name>Hydrogel sheet without Allogenic Mesenchymal Stem Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects between 18 and 80 years of age.

          2. Diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for longer
             than 4 weeks at the screening visit.

          3. Foot ulcer located in the instep, border or sole of the foot, with ulcer size between
             1 cm2 and 15 cm2.

          4. Ulcer graded I by Wagner grade, and extended to skin, subcutaneous tissue, but without
             exposure of muscle, tendon, bone or joint capsule.

          5. Ulcer is free of necrotic debris, exhibits no signs of clinical infection.

          6. Ulcer area blood circulation meets one of the following criteria

               -  A. Blood vessels around the ulcer detected by Doppler Test

               -  B. range of Ankle Brachial Index(ABI) was &gt; 0.7 to &lt; 1.3

               -  C. Transcutaneous oxygen pressure, (TcPO2) &gt; 30 mmHg.

          7. Is able to give written informed consent prior to study start and to comply with the
             study requirements.

        Exclusion Criteria:

          1. Ulcer is of non-diabetic pathophysiology.

          2. The ulcer has increased or decreased in size by ≥ 30% during the week after the
             Screening Visit.

          3. Is Human Immunodeficiency Virus (HIV) positive?

          4. Have severe hepatic deficiencies.

          5. Have a glycated hemoglobin A1c (HbA1c) level of &gt; 10%.

          6. Have allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.

          7. Require intravenous (IV) antibiotics to treat the target wound infection.

          8. Have severe renal failure including subject on renal dialysis.

          9. Pregnant or breast-feeding.

         10. Is unwilling to use an &quot;effective&quot; method of contraception during the study.

         11. Have evidence of current infection including pus drainage from the wound site.

         12. Have a clinically relevant history of alcohol or drugs abuse.

         13. Have postprandial blood sugar &gt; 350 mg/dl.

         14. Is not able to understand the objective of this study or to comply with the study
             requirements.

         15. Is considered by the investigator to have a significant disease which might have
             impacted the study.

         16. Is considered not suitable for the study by investigator.

         17. Have a history of malignancy within the last five years (except basal cell carcinoam
             in situ).

         18. Is currently or were enrolled in another clinical study within 60 days of screening.

         19. Have undergone wound treatments with growth factors, dermal substitutes, or other
             biological therapies within the last 30 days.

         20. Is receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic
             agents with unstable dose prior to 4 weeks from screening.

         21. Cannot maintain off-loading process

         22. Panel reactive antibody (PRA) levels ≥ 20%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David G. Armstrong, MD.Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander M. Reyzelman, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Nathan, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martinsville Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David G. Armstrong, MD.Ph D.</last_name>
    <phone>(+1)5203059393</phone>
    <email>armstrong@usa.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David G. Armstrong, MD.Ph D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>November 25, 2018</last_update_submitted>
  <last_update_submitted_qc>November 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

